125 related articles for article (PubMed ID: 20639853)
1. [The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease].
Iablonskaia AIu; Fedorova NV; Bel'gusheva ME
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(7):24-30. PubMed ID: 20639853
[TBL] [Abstract][Full Text] [Related]
2. A registry-based, case-control investigation of Parkinson's disease with and without cognitive impairment.
Papapetropoulos S; Ellul J; Polychronopoulos P; Chroni E
Eur J Neurol; 2004 May; 11(5):347-51. PubMed ID: 15142230
[TBL] [Abstract][Full Text] [Related]
3. Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature.
Kubo S; Iwatake A; Ebihara N; Murakami A; Hattori N
Parkinsonism Relat Disord; 2008; 14(2):166-9. PubMed ID: 17509924
[TBL] [Abstract][Full Text] [Related]
4. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment.
Kulisevsky J; Pagonabarraga J
Mov Disord; 2009 Jun; 24(8):1103-10. PubMed ID: 19353727
[TBL] [Abstract][Full Text] [Related]
5. [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease].
Li W; Zhao JH; Sun SG; Zhang JW; Suo AQ; Ma MM
Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(5):301-3. PubMed ID: 21419002
[TBL] [Abstract][Full Text] [Related]
6. Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders.
Siri C; Cilia R; Reali E; Pozzi B; Cereda E; Colombo A; Meucci N; Canesi M; Zecchinelli AL; Tesei S; Mariani CB; Sacilotto G; Zini M; Pezzoli G
Mov Disord; 2015 Apr; 30(5):696-704. PubMed ID: 25757654
[TBL] [Abstract][Full Text] [Related]
7. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial.
Witt K; Granert O; Daniels C; Volkmann J; Falk D; van Eimeren T; Deuschl G
Brain; 2013 Jul; 136(Pt 7):2109-19. PubMed ID: 23801735
[TBL] [Abstract][Full Text] [Related]
8. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Koziorowski D; Friedman A
Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
[TBL] [Abstract][Full Text] [Related]
9. [An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
Pilipovich AA; Golubev VL
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):41-7. PubMed ID: 15875942
[TBL] [Abstract][Full Text] [Related]
10. Early-stage cognitive impairment in Parkinson's disease and the influence of dopamine replacement therapy.
Miah IP; Olde Dubbelink KT; Stoffers D; Deijen JB; Berendse HW
Eur J Neurol; 2012 Mar; 19(3):510-6. PubMed ID: 22040383
[TBL] [Abstract][Full Text] [Related]
11. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
[TBL] [Abstract][Full Text] [Related]
12. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
[TBL] [Abstract][Full Text] [Related]
13. Addenbrooke's Cognitive Examination validation in Parkinson's disease.
Reyes MA; Perez-Lloret S; Roldan Gerschcovich E; Martin ME; Leiguarda R; Merello M
Eur J Neurol; 2009 Jan; 16(1):142-7. PubMed ID: 19049504
[TBL] [Abstract][Full Text] [Related]
14. Combined treatment in Parkinson's disease.
Wheatley D
Practitioner; 1983 Mar; 227(1377):446-7. PubMed ID: 6889232
[No Abstract] [Full Text] [Related]
15. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
Litvinenko IV; Odinak MM; Mogil'naya VI; Perstnev SV
Neurosci Behav Physiol; 2010 Feb; 40(2):149-55. PubMed ID: 20033305
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease.
Kaszás B; Kovács N; Balás I; Kállai J; Aschermann Z; Kerekes Z; Komoly S; Nagy F; Janszky J; Lucza T; Karádi K
Parkinsonism Relat Disord; 2012 Jun; 18(5):553-6. PubMed ID: 22405839
[TBL] [Abstract][Full Text] [Related]
17. Association between amantadine and the onset of dementia in Parkinson's disease.
Inzelberg R; Bonuccelli U; Schechtman E; Miniowich A; Strugatsky R; Ceravolo R; Logi C; Rossi C; Klein C; Rabey JM
Mov Disord; 2006 Sep; 21(9):1375-9. PubMed ID: 16705684
[TBL] [Abstract][Full Text] [Related]
18. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
Vale S
Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172
[TBL] [Abstract][Full Text] [Related]
19. Effects of depression and Parkinson's disease on cognitive functioning.
Norman S; Tröster AI; Fields JA; Brooks R
J Neuropsychiatry Clin Neurosci; 2002; 14(1):31-6. PubMed ID: 11884652
[TBL] [Abstract][Full Text] [Related]
20. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease.
Müller T; Kuhn W; Schulte T; Przuntek H
Neurosci Lett; 2003 Mar; 339(1):25-8. PubMed ID: 12618292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
